Stellantis to Announce Full Year 2022 Results on February 22

Stellantis to Announce Full Year 2022 Results on February 22

AMSTERDAM, February 3, 2023 - Stellantis N.V. announced today that its Full Year 2022 Results will be released on Wednesday, February 22, 2023.

A live webcast and conference call of the Full Year 2022 Results will begin at 2:00 p.m. CET / 8:00 a.m. EST on Wednesday, February 22, 2023.

The related press release and presentation material are expected to be posted under the Investors section of the Stellantis corporate website at HYPERLINK "file:///C:\Users\T5114EB\Desktop\Investor%20Relations\4Q22\Logistics\www.stellantis.com" www.stellantis.com at approximately 8:00 a.m. CET / 2:00 a.m. EST on Wednesday, February 22, 2023.

Details for accessing this presentation are available under the Investors section of the Stellantis corporate website at www.stellantis.com. For those unable to participate in the live session, a recorded replay will be accessible on the Company’s corporate website (www.stellantis.com).

About Stellantis

Stellantis N.V. (NYSE / MTA / Euronext Paris: STLA) is one of the world's leading automakers and a mobility provider. Its storied and iconic brands embody the passion of their visionary founders and today’s customers in their innovative products and services, including Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep_®, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. Powered by our diversity, we lead the way the world moves – aspiring to become the greatest sustainable mobility tech company, not the biggest, while creating added value for all stakeholders as well as the communities in which it operates. For more information, visit www.stellantis.com.

	@Stellantis		Stellantis		Stellantis		Stellantis
For more information, contact: Fernão SILVEIRA   + 31 6 43 25 43 41 – [email protected] Nathalie ROUSSEL   + 33 6 87 77 41 82 – [email protected]   [email protected] www.stellantis.com

Attachment

• Stellantis-FY-Results-Media-Advisory-EN

You May Also Be Interested In

• Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
• Farmers in Quebec readying for collection of pesticides and livestock/equine medications this Fall
• WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC